CHAIR: TBC
SPEAKER: David Ohlssen (Novartis Pharmaceuticals Corporation)
Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis
Authors: Karen L. Price, H. Amy Xia, Hwanhee Hong, Jouni Kerman, Haoda Fu, George Quartey, Cory R. Heilmann, Haijun Ma and Bradley P. Carlin;
Pharmaceutical Statistics, Volume 13, Issue 1, Pages 55–70, January/February 2014
Abstract | Paper+ | Slides
SPEAKER: Christine Fletcher (Amgen Ltd)
Subgroup analyses in cost-effectiveness analyses to support health technology assessments
Authors: Christy Chuang-Stein, Marie-Ange Paget, Carol Reid and Neil Hawkins;
Pharmaceutical Statistics, Volume 13, Issue 4, Pages 265-274, July/August 2014
Abstract | Paper+ | Slides
+Papers available to view from 18th November 2014 to 16th December 2014
For a flier advertising the event, please click here.Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
PSI are starting a book club! We will be reading/discussing non-technical books relevant to our roles. Participants will be split into smaller groups to network with each other and practice exercises.
In this short course, we will provide a statistical framework to incorporate external information into a trial. Bayesian Dynamic Borrowing designs based on the meta-analytic predictive (MAP) model will be detailed, and a practice session will be proposed with applications using the R package RBesT.
Our annual PSI Medical Statistics Careers Event, will be held online on Wednesday 2nd March 2022. The event will include a live online panel discussion and a virtual exhibition session.
We offer challenging work in a respectful and friendly global working environment surrounded by a world of innovation driven mindsets and practices.
In this role you will consult in the design of complex and innovative studies and clinical trial programs as well as Leading DMC/DSMB processes.
Joining us as Principal Biostatistician you will be responsible for providing statistical support of global clinical development programs in neuroscience.
